01/24/23 8:00 AMNasdaq : BIAF, BIAFW clinical triallow floatbioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory ResearchbioAffinity Technologies, Inc. today announced publication of“ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning” detailing results of the Company’ s clinical trial for its non-invasive diagnostic CyPath ® Lung in Respiratory Research, one of the leading peer-reviewed open access journals in the field of...RHEA-AIneutral
01/04/23 8:00 AMNasdaq : BIAF, BIAFW low floatbioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer TreatmentsbioAffinity Technologies, Inc. announced today that the U.S. Patent and Trademark Office has provided a Notice of Allowance for a patent application titled“ Porphyrin Compounds and Compositions Useful for Treating Cancer” for the targeted delivery of novel cancer treatments. “A little more than 1.9 million new cancer cases are expected to have been diagnosed...RHEA-AIpositive
12/19/22 11:33 AMNasdaq : BIAF low floatArgus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)Argus Research, an independent investment research firm, has launched Equity Research Report coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)Click Here to view full Argus Equity Research Report.COMPANY HIGHLIGHTS: Excerpts (as conveyed by ArgusRHEA-AIpositive
12/15/22 8:30 AMNasdaq : BIAF, BIAFW managementlow floatbioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical BenchbioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that they have made a key promotion and additions to their staff. Prior to that, she served as the Flow Cytometry and Microarray Technical Director at the...RHEA-AIneutral
12/01/22 8:00 AMNasdaq : BIAF, BIAFW low floatbioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO MeetingbioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment, today announced that David Elzi, Ph.D., bioAffinity Vice President of Research, will discuss his research into a possible mechanism by which the knock down of two genes kills...RHEA-AIneutral
11/14/22 7:30 AMNasdaq : BIAF, BIAFW earningslow floatbioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business UpdatebioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment, today reported its financial results for the third quarter of 2022 and provided a business update. Award of Therapeutic Patents in China, Mexico and Australia: In October, the...RHEA-AIpositive
11/10/22 8:15 AMNasdaq : BIAF, BIAFW managementlow floatbioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory BoardbioAffinity Technologies, Inc. announced Sheila Habib, MD, Director of Pulmonary Lung Nodule Clinic and the Lung Cancer Screening Program at the South Texas Veterans Health Care Systems’ Audie L. Murphy Memorial Veterans Hospital, and David Hill, MD, National Board Member of the American Lung Association and assistant clinical professor of medicine at Yale...RHEA-AIneutral
11/08/22 8:00 AMNasdaq : BIAF, BIAFW conferencesearningslow floatbioAffinity Technologies to Report Third Quarter 2022 Financial ResultsbioAffinity Technologies, Inc. today announced that the Company will host a conference call and audio webcast on Monday, Nov. 14, 2022, at 8 a.m. ET to discuss its corporate and financial results for the third quarter of 2022.. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted...RHEA-AIneutral
10/25/22 9:15 AMNasdaq : BIAF, BIAFW low floatbioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and AustraliabioAffinity Technologies, Inc. announced the People’ s Republic of China awarded a Certificate of Patent to the Company’ s wholly owned subsidiary OncoSelect ® for its patent“ Porphyrin Compounds and Compositions Useful for Treating Cancer” that is directed to novel compounds in which porphyrins are conjugated to chemotherapeutics for selective...RHEA-AIneutral
10/12/22 8:15 AMNasdaq : BIAF, BIAFW low floatbioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST ConferencebioAffinity Technologies, Inc., will present results of its research into the use of flow cytometry for analyzing the lung environment to detect diseases of the lung at the American College of Chest Physicians 2022 conference Oct. 16-19, 2022. The presentation, Sputum Analysis By Flow Cytometry To Assess Lung Health, will be part of the Lung Cancer Assessment...RHEA-AIneutral
